- Home
- OGN vs KNSA Comparison
OGN vs KNSA Comparison
Compare OGN & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGN
- KNSA
- Stock Information
- Founded
- OGN 1923
- KNSA 2015
- Country
- OGN United States
- KNSA United Kingdom
- Employees
- OGN N/A
- KNSA N/A
- Industry
- OGN Biotechnology: Pharmaceutical Preparations
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- OGN Health Care
- KNSA Health Care
- Exchange
- OGN Nasdaq
- KNSA Nasdaq
- Market Cap
- OGN 2.7B
- KNSA 2.6B
- IPO Year
- OGN N/A
- KNSA 2018
- Fundamental
- Price
- OGN $7.71
- KNSA $41.16
- Analyst Decision
- OGN Hold
- KNSA Strong Buy
- Analyst Count
- OGN 4
- KNSA 6
- Target Price
- OGN $15.75
- KNSA $51.33
- AVG Volume (30 Days)
- OGN 9.3M
- KNSA 487.8K
- Earning Date
- OGN 11-10-2025
- KNSA 10-28-2025
- Dividend Yield
- OGN 1.04%
- KNSA N/A
- EPS Growth
- OGN N/A
- KNSA N/A
- EPS
- OGN 1.91
- KNSA 0.47
- Revenue
- OGN $6,301,000,000.00
- KNSA $597,973,000.00
- Revenue This Year
- OGN N/A
- KNSA $62.63
- Revenue Next Year
- OGN $0.65
- KNSA $29.93
- P/E Ratio
- OGN $4.03
- KNSA $88.68
- Revenue Growth
- OGN N/A
- KNSA 55.68
- 52 Week Low
- OGN $6.18
- KNSA $17.82
- 52 Week High
- OGN $17.23
- KNSA $42.30
- Technical
- Relative Strength Index (RSI)
- OGN 46.71
- KNSA 65.14
- Support Level
- OGN $7.38
- KNSA $39.61
- Resistance Level
- OGN $7.88
- KNSA $41.27
- Average True Range (ATR)
- OGN 0.41
- KNSA 1.34
- MACD
- OGN 0.19
- KNSA 0.20
- Stochastic Oscillator
- OGN 90.88
- KNSA 82.58
About OGN Organon & Co.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.